-

11:38:35 PM

QGEN Stock News

QGEN - Qiagen NV

03/24/22 2:30 AM

NYSE : QGEN

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

QIAGEN N.V. today marked World TB Day by announcing its...

RHEA-AI

neutral

03/14/22 9:02 AM

NYSE : QGEN

QIAGEN Announces 20-F Annual Report Filing for 2021 Results

QIAGEN N.V. announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20- F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission. QIAGEN will provide printed copies of the 2021 Annual Report to shareholders free of charge upon request.

RHEA-AI

neutral

02/08/22 4:05 PM

NYSE : QGEN

covid-19

QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

Q4 2021: Net sales grow 2% to $582 million and adjusted diluted EPS rises 9% to $0.74- both above outlook Full-year 2021: Net sales grow 20% to $2.25 billion and adjusted diluted EPS rises 23% to $2.65- both above outlook 22% CER growth in non-COVID product sales, ahead of target for 20% CER Operating cash flow grows 40% to $639 million, free cash flow rises 38% to $449...

RHEA-AI

positive

02/07/22 1:30 AM

NYSE : QGEN

QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

QuantiFERON-TB Gold Plus, the fourth generation of the modern gold standard for TB detection, receives Chinese NMPA approval as test for active tuberculosis detection World Health Organization endorses QFT-Plus as alternative IGRA test for diagnosis of TB infection, recommends new QIAreach QFT for research use in epidemiological settings.

RHEA-AI

neutral

01/27/22 12:29 PM

NYSE : QGEN

QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes

QIAGEN N.V. today announced that its commitment to workplace diversity and gender equality has been...

RHEA-AI

very positive

01/25/22 1:30 AM

NYSE : QGEN

covid-19

QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance

QIAGEN N.V. today announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens. QIAGEN has shipped more than 35 QIAcuity systems to...

RHEA-AI

neutral

01/19/22 8:20 AM

NYSE : QGEN

QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021

QIAGEN N.V. announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05 Eastern Standard Time/ 22:05 Central European Time. A conference call is scheduled for Wednesday, February 9 at 15:00 Frankfurt time/ 14:00 London time/ 09:00 New York...

RHEA-AI

neutral

01/18/22 4:05 PM

NYSE : QGEN

QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products

QIAGEN N.V. today...

RHEA-AI

neutral

01/10/22 10:12 AM

NYSE : QGEN

QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version

QIAGEN N.V. today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution– which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample– with new tests and the launch of a higher-throughput version that includes a new level...

RHEA-AI

very positive

01/07/22 1:30 AM

NYSE : QGEN

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

QIAGEN N.V. today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems. QIAGEN has entered into two new collaborations that...

RHEA-AI

positive

Prev 1 2 3 4 5 6 7 8 9 10 Next

QGEN Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.qiagen.com
CeoThierry Bernard
Security nameQiagen NV
Issue typecs
SectorManufacturing
Sic code2836
Employees6178
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressHulsterweg 82
StateLimburg
CityVenlo
Zip5912 PL
CountryNetherlands
Phone31773556600

About Qiagen NV

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.